DEF: Chemed Corporation 2026 Annual Meeting Proxy Statement

Chemed Corporation has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation advisory vote.

Summary

• The Annual Meeting of Stockholders is scheduled for May 18, 2026, at 11:00 a.m. ET in Cincinnati, Ohio.
• Stockholders of record as of March 23, 2026, are entitled to vote.
• The agenda includes the election of nine directors, ratification of PricewaterhouseCoopers LLP as independent accountants, and an advisory vote on executive compensation.
• The company reported 14,614,676 shares of capital stock outstanding as of the record date.
• The proxy statement includes detailed disclosures on executive compensation, including performance-based metrics like Adjusted EPS and Return on Assets.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a standard, routine proxy filing that reflects stable corporate governance and a consistent approach to executive compensation, with no major surprises or controversial proposals.

Positives

• Strong stockholder support for executive compensation, with 88.63% positive votes in the 2025 Say On Pay vote.
• Executive compensation is heavily weighted toward performance-based metrics, with approximately 72.9% of the CEO's total compensation being performance-based.
• The company maintains a clawback policy for erroneously awarded compensation that conforms to NYSE requirements.
• The Board has separated the functions of CEO and Chairman to promote independence.
• All directors attended 100% of the board and applicable committee meetings during 2025.

Negatives

• The company provides perquisites to executives, including personal use of company aircraft and club memberships, which are detailed in the All Other Compensation table.
• The CEO's total compensation is 209 times the median pay of the company's employees.
• The company maintains an employment agreement with the CEO that includes potential excise tax gross-up provisions for certain legacy arrangements.
• The company's performance share units for the 2023-2025 period resulted in a payout of 124.1% for EPS targets, but 0% for TSR percentile performance.

Risks

• The company faces risks related to regulatory changes, material litigation, cybersecurity, and evolving technology risks including artificial intelligence.
• The company's compensation programs are subject to risks if performance metrics are not achieved, potentially impacting executive retention.
• The company's reliance on specific operating divisions (VITAS and Roto-Rooter) for financial performance creates concentration risk.

Future Outlook

The company continues to focus on long-term growth through its established executive compensation program, which links pay to performance metrics including Adjusted EPS and relative Total Shareholder Return (TSR). The company maintains its commitment to its current compensation philosophy following strong stockholder support.

Management Comments

• The Board believes that the current executive compensation program directly links executive compensation to financial performance and aligns the interests of executive officers with those of stockholders.
• The Board believes that the separation of the CEO and Chairman functions promotes independence and enhances corporate governance.

Industry Context

StockSavvy.ai notes that Chemed Corporation's compensation structure is consistent with industry standards for large-cap healthcare and service-oriented companies, emphasizing performance-based equity and long-term retention. The use of a specific peer group for benchmarking is a standard practice to ensure competitive compensation.

Comparison to Industry Standards

• The company's use of a peer group including ABM Industries, Option Care Health, and Encompass Health Corp. is consistent with benchmarking practices for diversified service and healthcare companies.
• The adoption of a majority voting standard for uncontested director elections aligns with modern corporate governance best practices.
• The use of a double-trigger for change-in-control severance payments is a standard market practice to protect stockholder interests.

Corporate Governance

Related Party Transactions

• A son of the CEO, Kevin J. McNamara, is employed by the company as a Vice President and Chief Strategy Officer, with compensation commensurate with his responsibilities.

Stakeholder Impact

• Shareholders are asked to vote on director elections, auditor ratification, and executive compensation.
• Employees participate in various benefit plans, including the Retirement Plan and non-qualified deferred compensation plans.

Next Steps

• Stockholders are urged to vote their shares by proxy via mail, telephone, or the Internet prior to the Annual Meeting.
• The company will hold its Annual Meeting of Stockholders on May 18, 2026.
• The company will file its 2027 proxy statement in early 2027.

Key Dates

Recommendation

The filing is a standard proxy statement for an annual meeting and does not contain material financial news or strategic shifts that would typically trigger a significant change in share price or a buy/sell recommendation.

Keywords

Chemed Corporation, Proxy Statement, Executive Compensation, Corporate Governance, Annual Meeting, Stockholder Vote, Board of Directors